 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
10th February 2006
F2G
Ltd Announces Successful Grant Application
Manchester, England, 10th February 2006 - F2G Limited, specialists in the research and development of new treatments for serious fungal infections in man, has received a European grant of £115,000 as part of the European Resistance Fungal Network consortium (EURESFUN).
F2G are
part of a network of institutions that have been awarded funding by
the EU to study approaches to the understanding, detection and prevention
of antifungal drug resistance in fungal pathogens. The network consists
of 8 academic institutions based around Europe, F2G Ltd and one other
biotechnology company. The study will last for three years and will
examine distinct resistance mechanisms in specific pathogens, and use
microarrays to detect novel resistance mechanisms. It is anticipated
that molecular investigations will uncover novel antifungal targets,
diagnostic tools and markers for resistance surveillance. In addition
the incidence and mechanisms of resistance in fungal pathogens around
Europe will be studied by collection and analysis susceptibility patterns/resistance
mechanisms of fungal strains from around Europe.
It is anticipated that the study will contribute significantly to the
understanding of antifungal drug resistance in Europe and provide better
diagnostic tools and therapeutic options.
F2G specialises in the research and development of new treatments for serious fungal infections in man. The Company was founded in 1998 on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. F2G is now advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. For more information visit www.f2g.com
Contact:
Dr Mike Birch
Operations Manager
Tel: (+44) 0161 785 1270
Fax: (+44) 0161 785 1273
Email: mikebirch@f2g.com
Tel +44 (0)161 785 1270 Fax +44 (0)161 785 1273 Email contact@f2g.com